ABSTRACT BACKGROUND Left ventricular assist devices (LVADs) have been used as an effective therapeutic option in patients
H eart transplantation is the gold standard treatment for patients with advanced heart failure resistant to medical therapy.
Because demand exceeds the availability of donor hearts, the use of mechanical circulatory support and left ventricular assist devices (LVADs) has emerged as an alternative form of therapy for such patients (1) . LVADs have been used as an effective therapeutic option in patients with advanced heart failure, either as a bridge to transplantation, as destination therapy, or in some patients, as a bridge to recovery (2, 3) . Improvement in myocyte histology and biochemistry, as well as in left ventricular anatomy, physiology, and hemodynamics, has been observed in patients with advanced heart failure receiving prolonged mechanical circulatory support (4, 5) . It has also been demonstrated that the use of LVADs improves the rate of survival, quality of life, and functional capacity in patients with advanced heart failure (6) (7) (8) (9) (10) . LVADs provide cardiac function, not only at rest, but also during exercise in patients with severe heart failure (11) (12) (13) (14) .
The improvement in cardiac function of implanted LVAD patients may be such that the pump could be removed and transplantation avoided with good long-term outcomes (15) (16) (17) (18) (19) . Sufficient recovery to allow device explantation has been observed in only 5% to 24% of patients (19) (20) (21) (22) (23) . However, a strategy of combining mechanical and pharmacological therapy may enhance further myocardial recovery and allow the device to be safely explanted in a larger proportion of LVAD implanted patients (24) (25) (26) (27) .
The explanted LVAD patients demonstrate improved quality of life, cardiac performance, and exercise performance several years following device removal (3, 12, 18, 28) . However, to what extent the explanted LVAD patients can restore their cardiac and physical function remains unknown. Therefore, in the present study, we tested the hypothesis that patients whose LVAD was explanted due to myocardial recovery using such protocols can achieve cardiac and physical functional capacities equivalent to those of healthy controls.
METHODS
STUDY DESIGN. This was a cross-sectional, observational study in which cardiac and respiratory measurements at rest and in response to maximal graded cardiopulmonary exercise testing were compared among the 4 groups: 1) heart transplant candidates;
2) LVAD implanted patients (on LVAD support);
3) LVAD explanted patients; and 4) healthy controls.
The LVAD implanted and LVAD explanted groups were consecutive patients subject to our previous investigations (12, 18, 26, 27) . Odense, Denmark) as we have previously described (11, 12, 29, 30) . Briefly, the Innocor device employs a rebreathing system that uses an oxygen-enriched mixture of an inert soluble gas (0.5% nitrous oxide) and an inert insoluble gas (0.1% sulfur hexafluoride) from a 4-l pre-filled anesthesia bag. Photoacoustic analyzers measure gas concentrations over a 5-breath interval. Nitrous oxide concentration decreases during the rebreathing maneuver at a rate proportional to pulmonary blood flow, allowing estimation of cardiac output. Three to 4 respiratory cycles are needed to obtain a value for nitrous oxide washout. After cardiac output measurement at rest, each patient was connected to the metabolic cart using a facemask.
Oxygen consumption, carbon dioxide production, and minute ventilation were measured. After 3 min of metabolic measurements at rest, heart transplant and Jakovljevic et al.
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continued to exercise through the measurement, and cool down was started after it was complete. At the same time during the rebreathing maneuver, peak arterial blood pressure was measured.
CALCULATIONS AND STATISTICAL ANALYSES. The cardiac power output was calculated from the product of cardiac output and mean arterial pressure using the following equation (12) BP ¼ blood pressure; HTx ¼ heart transplant candidate; LVAD ¼ left ventricular assist device.
RESULTS
Patients' demographic and clinical characteristics are presented in Table 1 . There were no significant differences in demographic details between the patients groups. LVEF was significantly lower in HTx compared with LVAD patients and controls (p < 0.01). Table 3 .
To obtain a perspective of the spans involved, the highest recorded cardiac and functional capacities Table 2 ).
To provide further insight into the cardiac and functional benefits associated with LVAD bridge-torecovery protocol, the data confirmed that the ratio between peak oxygen consumption and cardiac power output was the lowest in healthy controls Figure 1 , the diminution in cardiac functional capacity (peak cardiac power output) was most marked in the HTx group from 100% (the normalized average in healthy controls) to 25.6 AE 4.6% (p < 0.01), whereas the corresponding diminution in physical functional capacity (peak oxygen consumption) was to 33.7 AE 8.5% (p < 0.01).
Of patients who recovered sufficiently to enable LVAD explantation, 6 patients (37.5%) achieved peak exercise cardiac power output that fell within the normal range of age-and sex-matched healthy controls ( Figure 2 ), whereas 10 patients (62.5%) achieved peak exercise oxygen consumption levels within the range of healthy controls ( Figure 3) . By placing the relative values of cardiac versus physical functional capacities of the patients groups side by side as shown in Figure 1 , it is apparent that in these groups of patient cardiac functional capacity (peak cardiac power) was more severely impaired than physical impairments at peak exertion (peak oxygen consumption). Figures 2 and 3 also show a wellknown normal phenomenon of age-related decline findings suggest that a significant number of LVAD explanted patients can achieve cardiac and functional capacity similar to healthy controls confirming benefits of LVAD therapy and directing future investigations towards strategies to enhance myocardial recovery to allow for the device to be explanted.
Our data also suggest that these functional improvements can be sustained.
The data from the present study can also throw some light on a long-standing debate about whether the cardiac dysfunction per se or the peripheral STUDY LIMITATIONS. The cross-sectional study design and limited number of patients in each heart failure group may prevent generalization of the data.
Also, patients enrolled in the study were men. A longitudinal, multicenter study is therefore needed to allow assessments of cardiac and functional capacities Jakovljevic et al.
at different time points in both men and women. This will aim to identify strategies to enhance bridge-torecovery partway and define early markers of myocardial recovery to allow for LVADs to be explanted.
CONCLUSIONS
It is remarkable that dilated cardiomyopathy patients with refractory end-stage heart failure, following the judicious use of combined LVAD and medical therapies, were able to recover cardiac and physical functional reserve capacities. The extent of this recovery is that a significant number of them can achieve the levels equivalent to those of 
